This medicine is applied where additional symptomatic support is needed to address excessive, viscous respiratory secretions. It is commonly used for conditions characterized by persistent, fluctuating manifestations, such as chronic bronchitis and COPD, and also for acute respiratory episodes where symptoms become more noticeable.

Key Therapeutic Applications

The medication is generally applied for managing conditions where mucus is thick and difficult to clear, including Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and as supportive therapy in acute bronchitis and certain upper respiratory conditions like sinusitis. The medication is relevant for easing symptoms related to the ineffective, chesty cough that creates noticeable physiological strain.

“It provides supportive relief when symptoms interfere with routine activities by making it easier to expectorate secretions.”

This supportive role assists in the temporary but essential task of clearing the airways, which contributes to easing the overall symptom load during symptomatic periods for both adult and pediatric patient groups.

Quick Fact: Used for Managing Viscid Sputum and Chest Congestion

Official Population Eligibility for Бронхобос (Carbocisteine)

Official regulatory documents define specific populations who are eligible to use Бронхобос and those who must not use the medicine. Eligibility is governed by age, reproductive status, and the presence of certain concurrent medical conditions.

Use with Caution or Conditional Eligibility

• History of Gastroduodenal Ulcers: Official labeling advises that the medicine should be used with caution in patients who have a history of gastroduodenal ulcers.
• The Elderly: Use in older adult patients also requires caution as advised in the Summary of Product Characteristics (SmPC).
• Comorbidities: Certain formulations may be contraindicated in patients with rare hereditary problems, such as total lactase deficiency or glucose-galactose malabsorption, if the formulation contains those specific excipients.

Approved Age Groups

Бронхобос is generally approved for use in adults and in children aged 2 years and over (typically the oral solution formulation). The capsule or granule forms are often not recommended for children.

Interactions with other medicines and products

Official regulatory information for Carbocisteine (the active ingredient in Бронхобос) defines the interaction profile primarily through pharmacodynamic effects, establishing constraints based on therapeutic counter-effects and additive risk of adverse events. The medicine is not documented in major regulatory summaries as having clinically significant interactions mediated by cytochrome P450 (CYP) enzymes or drug transporters.

Contraindicated Combinations

Regulatory documents formally prohibit co-administration with medicinal products that work to antagonize the function of the mucolytic agent. Antitussive drugs and agents that depress bronchial secretions, such as atropine-like medicines, are contraindicated because their simultaneous use defeats the purpose of mucus clearance.

Caution and Additive Risk

Co-administration with specific drug classes is officially associated with an additive risk of gastrointestinal bleeding or ulceration. These classes include Non-Steroidal Anti-inflammatory Drugs (NSAIDs), corticosteroids (steroids), and antiplatelet medicines. This additive risk is specifically noted to be more clinically significant in patients with a history of or active gastroduodenal ulceration. There are no mandatory time-based administration separation rules and no officially documented interactions with food, alcohol, or supplements.

The mechanism of Бронхобос (Carbocisteine) is defined by its action as a mucoregulator and modulator of airway cellular signaling. The molecule targets key glycosyltransferase enzymes within the respiratory epithelial cells (goblet cells). This interaction alters the balance of mucin component synthesis, shifting the output toward mucins that are structurally less viscous. This modification reduces the viscoelasticity of respiratory secretions, which affects the physical transport of mucus and supports the optimization of mucociliary clearance function. The mechanism of action also involves engagement with signal transduction pathways. Carbocisteine functions as a suppressor of the pro-inflammatory NF-κB pathway and an activator of the Nrf2 pathway, the cell’s primary system for antioxidant defenses. This modulation affects the transcription of inflammatory mediators and modulates the stability of the respiratory epithelial lining. Since the primary action requires the synthesis of new, altered mucin, the full physiological change is dependent on cellular turnover rather than immediate surface-level chemical action.

How to Use Бронхобос (Carbocisteine) — Administration Guidelines

Бронхобос (Carbocisteine) is a mucolytic agent. It is strictly intended for oral administration. Proper use involves adhering to specific dosing schedules and administration techniques based on the patient's age and the phase of treatment.

Standard Dosing and Administration

Procedural Instructions

• Dosage Form: Carbocisteine is available in strengths such as 375 mg capsules and 250 mg/5 mL syrup.
• Administration: Capsules and tablets must be swallowed whole. Liquid forms must be measured using the device supplied with the product to ensure dose accuracy.
• Timing: Doses are generally taken in divided intervals throughout the day. It is often advised to take the medicine preferably without meals.
• Course Duration: Treatment duration is typically limited and should not exceed 8–10 days unless a physician directs otherwise.

Age-Specific Rules

Carbocisteine products are contraindicated in children under 2 years of age. Dosage for children aged 2 to 12 must follow the age-specific syrup regimen as listed on the product label. If a dose is missed, patients should continue with the next scheduled dose; do not double the dose to compensate.

Research Evidence / Overview of Studies for Бронхобос (Carbocisteine)

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Research examining the use of Carbocisteine in chronic respiratory conditions was largely conducted on Adults with stable Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. The evidence is derived primarily from large, double-blind Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies monitored long-term use, examining outcomes that describe episodic or acute changes, primarily focusing on the annual rate of acute flare-ups (exacerbations) and Health-Related Quality of Life.

Data show patterns related to fewer reported exacerbations observed in the study groups compared to control groups in many populations. However, research evaluating Carbocisteine's relationship with key lung function measures, such as FEV1, as assessed in the trials, reported limited or no observable changes. The overall evidence structure related to the exacerbation frequency outcomes is characterized by a high degree of methodological uniformity, but findings were mixed when studies specifically explored the medicine's potential in patients with mild-to-moderate COPD.

Research on Acute Respiratory Tract Infections (ARTIs)

Research was also evaluated for the use of Carbocisteine during acute, temporary illnesses, such as Acute Bronchitis. These research scenarios involved short-term, placebo-controlled RCTs typically monitoring responses over defined time intervals (often 4 to 8 days). Studies primarily evaluated patient-reported endpoints, including the measurement of acute symptom resolution and the patient-reported ease of expectoration. Research highlights changes measured during the study period, with short-term trials describing patterns of symptom duration that differed in the study groups. This evidence is generally considered to have a Moderate level of consistency.

Research Gaps and Uncertainty

The evidence for long-term effects beyond the typical 12-month study periods is not fully established. Studies monitored key lung function outcomes but evidence suggests that the differences observed in these areas were not statistically significant. Data for children younger than two years of age remain insufficient within the current research base. Research provides context but not individual predictions, and the results apply only to the specific populations and conditions under which they were conducted.

Common questions about Бронхобос (FAQ)

Q: Is Бронхобос a cough syrup or something different?

According to official product classification, Бронхобос is defined as a mucolytic agent. This means its primary function is to modify and manage thick, viscous respiratory secretions, rather than solely suppressing a cough. It is available for oral administration in various forms, including a syrup.

Q: Does the syrup form of Бронхобос contain alcohol or sugar?

The exact composition depends on the specific product formulation. Official documentation notes that certain syrup forms are described as 'sugar-free' but may contain excipients like liquid maltitol. Additionally, some adult syrup formulations contain a measurable amount of ethanol, or alcohol.

Q: What are the signs of taking too much Бронхобос, and what are the signs of this?

Regulatory information indicates that effects from taking more than the recommended amount may include symptoms related to gastrointestinal upset, such as nausea, vomiting, or diarrhea.

Q: Can I take Бронхобос with food, or does it need to be taken on an empty stomach?

Some official administration instructions contained in the regulatory documents advise taking the medicine preferably without meals. However, you should follow the specific guidance provided on your product labeling.

Q: What are the storage guidelines for keeping the liquid form of Бронхобос?

Official guidelines state the medicine should be stored at a temperature that does not exceed 30degree C and must be protected from light. It is also advised that the liquid form must not be refrigerated or frozen, as this could affect the product's stability.

Q: Is Бронхобос safe for people who have a history of asthma?

Official labeling indicates that the medicine should be used with caution in patients who have asthma or a history of bronchospasm (tightening of the airways). This caution is noted in regulatory documents, referencing the potential risk of bronchoconstriction.

Q: Does the research on Бронхобос cover use in non-smokers?

Studies, particularly long-term trials related to chronic conditions like COPD, have examined outcomes across different patient groups. Analysis of the research results indicates that the treatment's effect did not differ based on the patient's smoking status.

Q: Can I take Бронхобос if I am already taking blood-thinning medication?

Regulatory documents note that caution is advised when this medicine is co-administered with drugs known to cause gastrointestinal bleeding, such as antiplatelet medicines, due to an additive risk of adverse events.

Q: Does Бронхобос affect the action of antibiotics used for lung infections?

Regulatory summaries generally have not documented a direct or significant interaction between Carbocisteine and certain commonly prescribed antibiotics, such as Amoxicillin.

Q: Why is it necessary to ask a doctor about taking Бронхобос if I am elderly?

Regulatory documents formally advise that the use in older adults requires caution. This is primarily due to the potential for an increased risk of gastrointestinal adverse events in this population.

Q: Does Бронхобос treat the underlying cause of mucus or just the symptom?

The medicine is described in regulatory documents as a 'mucoregulator' that acts on the respiratory cells. Its mechanism involves altering the synthesis and structure of mucin components, thereby modifying the characteristic of the secretions.

Q: Is it okay to take Бронхобос with other cold and flu medicines?

Official regulatory documents contain specific contraindications for combining this medicine with other products. Specifically, taking it with cough suppressants (antitussives) or agents that depress bronchial secretions is prohibited, as this counteracts the medicine's function.

Q: Is the syrup form of Бронхобос safe for all age groups of children?

Official regulatory bodies generally restrict the use of Carbocisteine products. The medicine is formally contraindicated in children younger than two years of age.

Q: Does Бронхобос cause headaches?

Headache is listed in regulatory documents as a documented adverse reaction. It is classified as Rare, meaning that this side effect is reported to affect between 1 and 10 users in every 10,000.

Q: Are there any known withdrawal effects if I suddenly stop taking Бронхобос?

Official patient information leaflets often address the question of stopping the medicine. The documents indicate that information regarding specific withdrawal effects is generally considered 'not applicable.'

Q: Is Бронхобос a medicine that needs to be taken for a long time?

Treatment duration is typically limited to a short course, such as a maximum of 8–10 days, unless a physician directs otherwise. However, long-term use (up to 12 months) has been the subject of research studies for chronic respiratory conditions like COPD.

Q: How long does it usually take to feel the effect of Бронхобос?

Pharmacokinetic data shows the medicine is rapidly absorbed, with peak levels in the bloodstream reached in approximately two hours. However, the full physiological change is described as being dependent on cellular turnover, meaning noticeable symptom improvement may take longer.

Q: Can I take a vitamin C supplement with Бронхобос?

Official regulatory information provided in the interactions section states that there are no officially documented interactions with supplements.

Q: Can a person with diabetes use the syrup formulation of Бронхобос?

Certain formulations, specifically the sugar-free oral solutions, are explicitly described in regulatory documents as being suitable for administration to individuals who have diabetes.

Official Storage and Disposal Requirements

Storage and disposal of Бронхобос (Carbocisteine) must strictly follow the conditions specified in official regulatory labeling to ensure product stability and safety.